
Alkermes (ALKS) Stock Forecast & Price Target
Alkermes (ALKS) Analyst Ratings
Bulls say
Alkermes is well-positioned to capitalize on the growing demand for treatments for sleep disorders, particularly with its focus on developing orexin-based drugs. The company has shown promising results with alixorexton so far and has a strong pipeline of potential treatments in development. Additionally, Alkermes' partnerships with other companies and its use of proprietary technology give it a competitive advantage in the biotech industry. Furthermore, the company's strong financials, with a steady increase in revenue and a healthy balance sheet, provide a solid foundation for future growth and development.
Bears say
Alkermes is reliant on third-party partnerships for drug formulation which can lead to potential revenue volatility, and its current main revenue driver is in a highly competitive market with limited differentiation. In addition, their recent drug TAK-360 in phase 2 trials for NT2/IH has not yet been proven effective and has received little data, making it a risky investment.
This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares